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Abstract
Background: The European Working Group on Sarcopenia in Older People (EWGSOP2) recommends grip strength
and chair stand tests to be used as primary defining measures. It is unclear how either test affects prevalence
estimates.
Methods: This cross-sectional study involved 3498 community-dwelling participants (40–84 years) from the 7th
Tromsø Study survey (2015–2016). We used grip strength, five-repetition chair stands, four-meter Walk Speed Test,
Timed-Up-and-Go (TUG) and Dual-Energy X-ray Absorptiometry measurements. Data were analyzed using multiple
linear regression models and ROC-curves.
Results: Probable and confirmed sarcopenia prevalence was 1.3 and 4.4% based on grip strength and chair stands,
respectively. There was very low agreement between grip strength and chair stand cut-offs (κ = 0.07), with only
4.3% of participants defined as having probable sarcopenia overlapping in the two criteria. Participants with grip
strength-based sarcopenia had lower mean height, weight, waist circumference, and appendicular lean mass
relative to body height (ALMheight
2) than non-sarcopenic participants (all p < 0.001), after adjusting for multiple
covariates. Conversely, participants with chair stand-based sarcopenia had similar height, higher weight, waist
circumference and body fat% compared to non-sarcopenic participants (all p < 0.05). Area-under-curves (AUCs) for
TUG-time were significantly larger when using chair stand instead of grip strength cut-offs (0.86, 95% CI 0.84–0.89
vs. 0.75, 95% CI 0.69–0.83).
Conclusions: Using chair stands instead of grip strength more than doubled probable sarcopenia prevalence
across all ages. The two measures defined individuals of contradictory anthropometrics, body composition, and
dissimilar physical function to have probable sarcopenia. Researchers should further evaluate the consequences of
using different strength measures in the EWGSOP2 definition to classify sarcopenia.
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Background
Sarcopenia is a muscle disease characterized by progres-
sive loss of strength, muscle mass and physical function
with increasing age [1]. Sarcopenia predicts several ad-
verse outcomes, including falls and fractures, reduced
quality of life, cognitive impairment and increased mor-
tality [2–5]. Several studies have shown that regular re-
sistance exercise effectively prevents sarcopenia in older
adults, effects that may be further enhanced by simultan-
eously increasing protein intake [6–8]. However, clini-
cians rely on adequate disease-defining thresholds and
guidelines to direct effective treatments, and implemen-
tation of the sarcopenia diagnose is currently hindered
by a lack of international consensus over a common op-
erational definition [9].
Since the 1990s, reported sarcopenia prevalence have
ranged between 10 to 40% in community-dwelling indi-
viduals aged 55 or more [10]. The substantial range of
these estimates are likely the result of continuous revi-
sions of the disease definition, parallel establishment of
several international sarcopenia work groups and use of
different criteria. The revised sarcopenia definition from
the European Working Group on Sarcopenia in Older
People (EWGSOP2) now recognizes muscle strength as
the primary defining measure in contrast to the previous
definition that emphasized muscle mass [11, 12]. EWG-
SOP2 guidelines recommend grip strength or chair stand
tests for determination of upper- or lower-body strength
respectively, and have called for validation of their new
operational criteria in different populations [11]. To en-
sure proper diagnosis of sarcopenia status, it is import-
ant to evaluate how the strength measures perform
against each other, as previous research have reported
weak associations between strength in upper- or lower-
body extremities, in addition to different associations
with physical function [13, 14]. It is thus unclear
whether grip strength and chair stand tests can be used
interchangeably as primary defining measures, and how
selecting one or the other may affect sarcopenia preva-
lence estimates.
We aimed to investigate sarcopenia prevalence accord-
ing to the EWGSOP2 definition in a Scandinavian popu-
lation, and to evaluate consequences of using either
upper-body or lower-body strength assessment as pri-
mary defining measures.
Methods
Study design and participants
The Tromsø Study is an ongoing population-based study
in Tromsø, Northern Norway, with seven completed
waves of data collection since 1974 [15]. The current
study analyzed data from the 7th survey (Tromsø 7,
2015–16), with procedures described elsewhere (see also
Additional file 1) [16]. We included community-dwelling
participants aged 40–84 years with complete data from
physical function and body composition measurements
(n = 3498).
Strength and physical function assessment
Grip strength testing followed the Southampton proto-
col procedures [17]. Participants were seated and
instructed to hold a Jamar+ Digital Dynamometer (Pat-
terson Medical, Warrenville, IL, USA) in a 90° elbow
joint angle, and squeeze the dynamometer with maximal
effort. The test was repeated three times per hand, and
the present study analyzed the highest of the six values.
The dynamometer was brand new and freshly calibrated
by the manufacturer.
The five-repetition chair stand test, part of the Short
Physical Performance Battery (SPPB) [18], was used for
assessment of leg muscle strength. Participants were
instructed to completely rise up from a seated position
five times as fast as possible, without stopping and to
keep their arms crossed over their chest. Participants ini-
tially practiced one chair rise before the main test. Using
a stopwatch, total time was measured in seconds (s)
from the initial seated position until the participant had
risen for the last time and were standing up. The test
was aborted if participants used their arms for rising, if
more than 60 s passed, or if there were uncertainties re-
garding the patient’s safety.
The Timed-Up-and-Go (TUG) test was used to assess
overall physical function, where participants were
instructed to rise unaided from a chair (starting point),
walk three meters (m) forward, walk back to the chair
and be seated again (finish). They were asked to move
with a normal, everyday pace and were aided by mark-
ings on the floor that indicated where to turn. The total
time in s was recorded between the starting point and
finish using a stopwatch.
Participants also performed the four-meter walk speed
(4MWS) test twice, where they were instructed to walk
in their regular pace, stopping by a four-meter marking
on the floor. The total time was measured using a stop-
watch and we calculated walk speed in m per s (m/s) by
dividing the total time by four. The faster of the two tri-
als was used in the analyses.
Body composition measurement
Body composition was measured by Dual-Energy X-ray
Absorptiometry (DXA) using a Lunar Prodigy device
(GE Healthcare Lunar, Madison, WI, USA). Participants
underwent a whole-body scan lasting approximately
10 min. Trained technicians inspected each completed
scan picture and made appropriate adjustments to the
regions of interest in accordance with the manufacturer’s
guidelines. The device was calibrated each morning
using a phantom, and post-scan analyses were
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performed in enhanced mode using enCore version 17
(GE Healthcare Lunar, Madison, WI, USA). For the
present study, we extracted data on appendicular lean
mass (ALM; lean mass in arms + legs) and total body fat
percentage (TBF%).
Sarcopenia definition
Probable or confirmed sarcopenia were defined accord-
ing to EWGSOP2 thresholds [11]. Probable sarcopenia
was defined as having grip strength < 16 kg for women
and < 27 kg for men, or taking > 15 s to perform five
chair stand repetitions for both men and women. Con-
firmed sarcopenia was defined as further having ALM
relative to squared body height (ALMheight
2) < 5.5 kg/me-
ters squared (kg/m2) for women and < 7 kg/m2 for men,
in line with EWGSOP2 recommendations to use a stan-
dardized approach to this parameter [19]. We chose to
analyze the entire sample from age 40–84 in order to in-
vestigate and compare how prevalence estimates be-
tween grip strength-based and chair stand-based
sarcopenia status might progress from middle age to
older age.
Covariates
Weight (kg) and height (m) were measured in light
clothing without shoes, and body mass index (BMI) was
calculated as kg/m2. Waist circumference (centimeter;
cm) was measured with a measuring tape at the umbil-
ical level. Participants answered a comprehensive ques-
tionnaire including data on level of education (primary,
upper secondary, college/university < 4 years, and col-
lege/university ≥ 4 years) current smoking and diabetes,
and previous cardiovascular disease (CVD; stroke and
myocardial infarction). Trained research personnel
performed all measurements according to standard
procedures.
Statistical analysis
We reported percentages (%) for sarcopenia prevalence,
and used means, standard deviations (M ± SDs) and 95%
confidence intervals (95% CIs) to present population
characteristics. We standardized total sample prevalence
using the European Standard Population 2013 [20]. The
Student’s t-test was used to compare groups of sarcope-
nia status for continuous variables and the chi-square
test was used for categorical variables. Cohen’s Kappa
(κ) was used to determine the level of agreement be-
tween grip strength and chair stand cut-offs for classifi-
cation of probable sarcopenia and subsequent confirmed
sarcopenia. We used logistic regression to investigate sex
differences in sarcopenia components and presented this
with age-adjusted p-values. We used multiple linear re-
gression models to analyze the independent association
between either grip strength or chair stand-based
probable sarcopenia, with anthropometrics and body
composition variables. In these analyses, we reported un-
standardized beta coefficients with 95% CIs and stan-
dardized beta (β) coefficients. Model 1 was unadjusted
while model 2 (fully adjusted) was adjusted for sex, age,
smoking status, CVD, diabetes and education. Residuals
were inspected for normality ahead of regression ana-
lyses. We used receiver operating characteristic (ROC)
curves, and reporting of area under curve (AUC) with
95% CIs to inspect associations between sarcopenia pa-
rameters and either the grip strength or chair stand cri-
teria. All statistical analyses were performed using Stata
software version 15.1 (StataCorp, College Station, TX,
USA).
Results
Sample characteristics by sarcopenia status
Table 1 shows descriptive data stratified by groups of sarcope-
nia status: no sarcopenia, probable sarcopenia (defined by
meeting the grip strength or the chair stand cut-off) and con-
firmed sarcopenia (defined by having probable sarcopenia +
meeting the ALMheight
2 cut-off). As indicated by the 95% CIs,
age was linearly increased while height was decreased in the
probable sarcopenia group only. Weight, BMI and waist cir-
cumference were higher in participants with probable sarco-
penia but lower in participants with confirmed sarcopenia,
compared to non-sarcopenic participants. Participants with
probable sarcopenia had higher TBF% than non-sarcopenic
participants, while participants with confirmed sarcopenia
had lower. Women with probable sarcopenia had higher
ALMheight
2 compared to the non-sarcopenic group while
women with confirmed sarcopenia had lower ALMheight
2. For
men, ALMheight
2 decreased linearly over probable and con-
firmed sarcopenia groups respectively. Participants with prob-
able sarcopenia were significantly more likely to be female
(75.6 vs. 57.6%), diabetic (15.4 vs. 5.4%) and to have lower
education level than non-sarcopenic participants (p < 0.001
for all). In addition, participants with probable and confirmed
sarcopenia expressed slower walk speed, poorer TUG per-
formance, lower grip strength and poorer chair stand per-
formance compared to participants without sarcopenia.
Sample prevalence of probable and confirmed sarcopenia
Table 2 shows that using grip strength as the primary criteria
resulted in 1.1% being classified as having probable sarcope-
nia among 40–84 year olds, while the corresponding preva-
lence for using chair stands was 3.9%. Total sample
prevalence of confirmed sarcopenia only was 0.3% combined
with ALMheight
2. Corresponding numbers for chair stands
was 0.5% when combined with ALMheight
2. The total age-
standardized sample prevalence for probable and confirmed
sarcopenia combined was 1.3% using grip strength as the pri-
mary criteria and 4.4% using chair stand as the primary cri-
teria. Grip strength-based prevalence of probable and
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confirmed sarcopenia remained fairly constant (0.6–0.7%) for
ages 40–69, increasing to 1.2% in ages 70–74, to 2.5% in ages
75–79 and to 8.4% in ages 80+ years (Fig. 1). Prevalence of
probable and confirmed sarcopenia defined by chair stands
increased progressively from 1.6 to 2.7, 4.5, 7.8, 10.3 and
20.4% for ages 40–59, 60–64, 65–69, 70–74, 75–79 and 80+
years, respectively. Allowing any strength criteria to define
sarcopenia resulted in a total sample prevalence of 4.5% (n=
205) with probable sarcopenia and 0.7% (n= 30) with con-
firmed sarcopenia (Table 2).
Agreement between probable and confirmed sarcopenia
status
Figure 2 shows that 9 out of 205 (4.3%) participants
overlapped between grip strength and chair stand cri-
teria, indicating a very low level of agreement (κ = 0.07,
95% CI 0.02–0.12) between the two measures of
probable sarcopenia. For subsequent determination of
confirmed sarcopenia, 3 out of 30 (10.0%) participants
overlapped, also indicating a very low level of agreement
(κ = 0.18, 95% CI 0.00–0.36). Excluding overlapping par-
ticipants, those with initial probable sarcopenia deter-
mined by grip strength were more likely to also have
confirmed sarcopenia (24.1%) than those determined by
chair stand (12.0%).
Sarcopenia parameter cut-offs and sex differences
Table 3 shows that there were no significant differences
in proportions of men and women reaching the EWG-
SOP2 thresholds for grip strength (1.3 vs. 1.4%) or TUG
(0.1 vs. 0.3%). The chair stand test defined a significantly
larger proportion of women than men to have probable
sarcopenia (7.2 vs. 3.6%, p < 0.001). Likewise, a larger
proportion of women compared to men had slow walk
Table 1 Descriptive characteristics of study participants according to sarcopenia status






Age-standardized prevalence (%)a – – 4.5 0.7
Age (yrs) 66.0 ± 9.0 (65.7–66.3) 65.6 ± 8.9 (65.2–65.9) 71.6 ± 7.8 (70.5–72.7) 77.5 ± 4.6 (75.8–79.2)
Weight (kg) 77.34 ± 15.0 (76.8–77.8) 77.3 ± 14.9 (76.8–77.8) 79.8 ± 15.8 (77.6–82.0) 62.0 ± 12.8 (57.2–66.8)
Height (cm) 168.6 ± 9.3 (168.3–168.9) 168.9 ± 9.2 (168.6–169.2) 164.5 ± 9.5 (163.2–165.8) 167.7 ± 10.2 (163.9–171.6)
Women (n, %) 2047 (58.5) 1879 (57.6) 155 (75.6)b 13 (43.3)
BMI (kg/m2) 27.1 ± 4.3 (27.0–27.3) 27.0 ± 4.2 (26.9–27.2) 29.4 ± 5.0 (28.7–30.1) 21.8 ± 2.8 (20.8–22.9)
Waist circumference (cm)c 95.0 ± 12.5 (94.5–95.4) 94.7 ± 12.4 (94.3–95.1) 100.6 ± 12.8 (98.8–102.3) 86.8 ± 12.4 (82.1–91.5)
Total body fat percentage (%) 34.7 ± 7.8 (34.4–35.0) 34.4 ± 7.7 (34.1–34.6) 40.5 ± 6.9 (39.5–41.4) 30.5 ± 7.0 (27.8–33.1)
ALMheight
2
Women (kg/m2) 6.9 ± 0.9 (6.8–6.9) 6.9 ± 0.9 (6.8–6.9) 7.1 ± 1.1 (7.0–7.3) 5.1 ± 0.3 (4.9–5.3)
Men (kg/m2) 8.4 ± 1.0 (8.4–8.5) 8.5 ± 0.9 (8.4–8.5) 8.2 ± 0.8 (7.9–8.4) 6.5 ± 0.5 (6.2–6.7)
Current smoker (n, %)c 388 (11.2) 356 (11.0) 29 (14.6) 3 (10.0)
CVD, previous (n, %)c 265 (7.8) 239 (7.5) 20 (10.3) 6 (21.3)b
Diabetes, current (n, %)c 200 (5.9) 169 (5.4) 30 (15.4)b 1 (3.5)
Education (n, %)c
Primary/partly secondary 1173 (34.4) 1063 (33.3) 101 (52.9)b 9 (31.0)
Upper secondary 937 (27.5) 871 (27.3) 56 (29.3)b 10 (34.5)
Tertiary, short 604 (17.7) 578 (18.1) 20 (10.5)b 6 (20.7)
Tertiary, long 696 (20.4) 678 (21.3) 14 (7.3)b 4 (13.8)
Walk speed (m/sec) 1.2 ± 0.2 (1.1–1.2) 1.2 ± 0.2 (1.2–1.2) 0.9 ± 0.2 (0.9–1.0) 0.8 ± 0.2 (0.8–0.9)
TUG (sec) 8.6 ± 2.3 (8.6–8.7) 8.4 ± 2.0 (8.4–8.5) 11.4 ± 3.2 (11.0–11.8) 12.8 ± 3.4 (11.6–14.1)
Grip strength
Women (kg) 27.4 ± 5.2 (27.2–27.6) 27.8 ± 4.8 (27.6–28.0) 23.1 ± 6.2 (22.1–24.0) 19.3 ± 7.1 (15.0–23.6)
Men (kg) 46.7 ± 9.0 (46.3–47.2) 47.3 ± 8.6 (46.9–47.8) 36.8 ± 10.5 (33.8–39.7) 29.6 ± 4.0 (27.5–31.7)
Chair rises, 5 repetitions (sec) 9.9 ± 3.4 (9.8–10.0) 9.4 ± 2.3 (9.3–9.5) 17.6 ± 6.7 (16.7–18.5) 16.5 ± 4.1 (15.0–18.0)
Numbers are mean ± SD (95% CI) or n (%). Probable sarcopenia is defined by either grip strength or chair stand cutoffs. Confirmed sarcopenia is defined by
ALMheight
2 cutoffs. ALMheight
2 Appendicular Lean Mass relative to squared body height, CVD Cardiovascular Disease (includes myocardial infarction and stroke), TUG
Timed-Up-and-GO test. aTotal sample prevalence standardized according to European Populations 2013. bSignificantly different at P < 0.01 level from the non-
sarcopenic group according to chi2 test. cMissing data present: 0.3% for waist circumference, 1.2% for current smoker, 2.7% for previous CVD, 3.4% for current
diabetes, 2.6% for education levels. The Tromsø Study 2015–16
Johansson et al. BMC Geriatrics          (2020) 20:461 Page 4 of 11
speed (7.3 vs. 5.1%, p = 0.006). A higher proportion of
men compared to women had low ALMheight
2 (5.9 vs.
4.4%, p = 0.038). Figure 3 further illustrates the sex dif-
ferences in sarcopenia parameters, such as grip strength
for women (Fig. 3a) and men (Fig. 3b), chair stands for
women (Fig. 3c) and men (Fig. 3d), and ALMheight
2 for
women (Fig. 3e) and men (Fig. 3f).
Probable sarcopenia measures as independent predictors
of anthropometrics and body composition
The fully adjusted regression models (model 2) pre-
sented in Table 4 shows that sarcopenic participants
based on grip strength weighed less (− 8.8 kg, 95% CI −
12.8 to − 4.7) and were shorter (− 6.1 cm, 95% CI − 8.0
to − 4.1) compared to non-sarcopenic participants. In
contrast, sarcopenic participants based on chair stands
weighed more (5.0 kg, 95% CI 3.0–6.9) than non-
sarcopenic participants, while there was no height differ-
ence. Model 2 further shows that participants with prob-
able sarcopenia according to grip strength had lower
BMI (− 1.1 kg/m2, 95% CI − 2.5 to − 0.2), waist circum-
ference (− 3.9 cm, 95% CI − 7.5 to − 0.3), and ALMheight
2
(− 0.5 kg/m2, 95% CI − 0.8 to − 0.2) compared to non-
sarcopenic participants. In contrast, participants with
probable sarcopenia according to chair stand perform-
ance had higher BMI (1.6 kg/m2, 95% CI 0.9 to 2.2),
waist circumference (5.5 cm, 95% CI 3.8 to 7.3) and
TBF% (2.7%, 95% CI 1.6 to 3.7) compared to their non-
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0 (0.00) 0 (0.00) 2 (0.23) 4 (0.62) 12 (3.02) 12 (6.28) 30 (0.86) 0.69
Numbers are n (%). EWGSOP2 European Working Group on Sarcopenia in Older People revised definition, ALMheight
2 Appendicular Lean Mass relative to squared
body height. aTotal sample prevalence standardized according to European Populations 2013. The Tromsø Study 2015–16
Fig. 1 Prevalence of probable and confirmed sarcopenia based on grip strength or chair stand tests across age groups. The Tromsø Study 2015–16
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sarcopenic counterparts after adjusting for all covariates
in model 2, including age and sex (Table 4).
Associations between sarcopenia parameters and
probable sarcopenia cut-off points
The ROC-analysis showed no significant differences be-
tween the AUCs for walk speed, TUG or ALMheight
2 in
relation to grip strength-based probable sarcopenia
(Fig. 4a). For chair stand-based sarcopenia, the AUC for
walk speed (0.79, 95% CI 0.75–0.82) was significantly
larger than the AUC for ALMheight
2 (0.56, 95% CI 0.52–
0.60), while the AUC for TUG was significantly larger
(0.86, 95% CI 0.84–0.89) than all other sarcopenic
parameters (Fig. 4b). In addition, the AUC for TUG was
significantly larger when using chair stands (Fig. 4b) to
classify probable sarcopenia compared to using grip
strength (Fig. 4a; 0.76, 95% CI 0.69–0.83).
Discussion
In this population-based study of 3498 women and men
aged 40–84 years, the age-standardized prevalence of
probable and confirmed sarcopenia was 1.3% when using
grip strength, and 4.4% when using chair stands as pri-
mary sarcopenia defining measure. The chair stand test
defined significantly more women than men as sarcope-
nic, and total sample prevalence based on chair stands
was more than doubled across all age groups compared
to using grip strength. Prevalence of chair stand-based
probable sarcopenia also increased progressively from
age 40–59, whereas the prevalence of grip strength-
based probable sarcopenia increased notably first at age
70–74. In addition, we present novel data showing major
differences in anthropometrics, body composition and
physical function between participants depending on
whether grip strength or chair stands were used to de-
fine probable sarcopenia.
Recently the UK Biobank reported a 5.3% prevalence
of probable sarcopenia for 40–70 year olds [21], which
differs from the 1.3% prevalence reported in the current
study even though our participants were older. This
could partly be influenced by instrumental differences,
Fig. 2 Agreement and overlap between cut-offs for probable and confirmed sarcopenia. κ = Cohen’s Kappa statistic, ALMheight2 = Appendicular
Lean Mass relative to squared body height. The Tromsø Study 2015–16
Table 3 Proportions of men and women crossing the
sarcopenic threshold for each separate EWGSOP2 parameter
EWGSOP2 parameter Men (n = 1451) Women (n = 2047) P
Grip strength 19 (1.31) 29 (1.42) 0.783
Chair stands 52 (3.58) 147 (7.18) < 0.001
ALMheight
2 86 (5.93) 90 (4.40) 0.038
Walk speeda, b 74 (5.10) 150 (7.33) 0.006
TUGa, c 1 (0.07) 7 (0.34) 0.129
Numbers are n (%). P-values are age-adjusted by logistic regression. aWalk
speed and TUG had missing data for n = 2 and n = 3 participants respectively.
bEWGSOP2 thresholds for walkspeed is ≤ 0.8 m/s. c EWGSOP2 thresholds for
TUG is ≥ 20 s. ALMheight
2 = Appendicular Lean Mass relative to squared body
height, TUG = Timed-Up-and-GO test. The Tromsø Study 2015–16
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as we used the electronic version of the Jamar dyna-
mometer compared to the hydraulic version commonly
used by others. Grip strength differences between Euro-
pean regions might also influence this finding, as a simi-
larly low prevalence (1.8%) of probable sarcopenia was
recently found among older adults aged 70 years from
northern Sweden [22]. Additionally, previous Tromsø
Study findings indicate a temporal increase in muscle
strength in the current study population [23].
Fig. 3 Presentation of study sample data for individual sarcopenic parameters stratified by sex across ages 40–84. a = grip strength among
women with cut-off < 16 kg. b = grip strength among men with cut-off < 27 kg. c = five-repetition chair stands among women with cut-off > 15 s.
d = five-repetition chair stands among men with cut-off > 15 s. e = appendicular lean mass relative to body height among women relative with
cut-off < 5.5 kg/m2. f = appendicular lean mass relative to body height among men with cut-off < 7.0 kg/m2. Cut-offs are based on the EWGSOP2
definition and are represented by the red dashed line. The Tromsø Study 2015–16
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Few large, population-based studies have compared
the outcome of using grip strength or chair stand tests
to define individuals as having probable sarcopenia ac-
cording to the updated EWGSOP2 criteria. The Korean
Frailty and Aging Cohort Study reported that among
2099 participants aged 70–84, 13.7% had grip strength-
based probable sarcopenia and 13.6% had chair stand-
based probable sarcopenia [24]. Their higher prevalence
estimates are likely explained by the larger proportions
of older participants in their study. Similar to our study,
they found that significantly more women than men
were defined as sarcopenic by chair stands, but con-
versely also found that significantly more men than
women were sarcopenic by grip strength. We speculate
Table 4 Independent associations for EWGSOP2 cut-offs for muscle strength with anthropometric data and body composition
parameters
Independent variable Dependent variable Model 1 Model 2
Beta (95% CI) β Beta (95% CI) β
Grip strength probable sarcopenia cut-off Weight (kg) −8.6 (−12.9 to − 4.4) −0.067 −8.8 (− 12.8 to − 4.7) −0.064
Height (cm) − 7.3 (− 10.0 to − 4.7) −0.092 −6.1 (− 8.0 to − 4.1) −0.071
BMI (kg/m2) −0.7 (− 1.9 to 0.6) − 0.018 − 1.1 (− 2.5 to − 0.2) − 0.028
Waist circumference (cm) −2.0 (− 5.5 to 1.6) −0.018 −3.9 (− 7.5 to − 0.3) −0.034
Total body fat (%) 1.4 (−0.8 to 3.7) 0.021 0.1 (− 2.1 to 2.3) 0.002
ALMheight
2 (kg/m2) −0.7 (− 1.0 to − 0.3) −0.065 − 0.5 (− 0.8 to − 0.2) −0.046
Chair stand probable sarcopenia cut-off Weight (kg) 2.1 (−0.1 to 4.2) 0.032 5.0 (3.0 to 6.9) 0.075
Height (cm) −2.9 (−4.2 to − 1.6) −0.074 0.7 (−0.3 to 1.6) 0.017
BMI (kg/m2) 1.7 (1.1 to 2.4) 0.093 1.6 (0.9 to 2.2) 0.082
Waist circumference (cm) 5.3 (3.5 to 7.1) 0.098 5.5 (3.8 to 7.3) 0.100
Total body fat (%) 5.2 (4.1 to 6.3) 0.154 2.7 (1.6 to 3.7) 0.100
ALMheight
2 (kg/m2) −0.3 (−0.4 to −0.1) −0.052 0.1 (−0.0 to 0.3) 0.021
Numbers are unstandardized beta-coefficients (Beta) with 95% CIs and standardized beta coefficients (β). Coefficients indicate the resulting change on
anthropometric and body composition data of reaching the probable sarcopenia cut-off point for either grip strength or chair stand tests. Model 1 is unadjusted.
Model 2 (final model) is adjusted for sex, age, current smoker, CVD, current diabetes and educational level. ALMheight
2 = Appendicular Lean Mass relative to
squared body height. The Tromsø Study 2015–16
Fig. 4 ROC-curves presenting sarcopenia parameter classification of grip strength and chair stand cut-offs for probable sarcopenia. a =
classification of grip strength-based probable sarcopenia by walkspeed, TUG and ALMheight
2. b = classification of chair stand-based probable
sarcopenia by walkspeed, TUG and ALMheight
2. AUC = Area Under the Curve, ALMheight2 = Appendicular Lean Mass relative to squared body
height, TUG = Timed-Up-and-GO test. The Tromsø Study 2015-2016
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that these differences could be partly explained by their
higher inclusion of rural participants in contrast to the
Tromsø Study which mainly involves urban residents.
However, this sex discrepancy warrants elucidation, and
it is also unclear why the total sample prevalence of
probable sarcopenia was not higher in their study when
using chair stands compared to grip strength, a finding
now reported by us and by others previously [25].
After adjusting for multiple covariates, we found that
participants with grip strength-based probable sarcope-
nia were shorter, lighter and less muscular than their
non-sarcopenic counterparts, while participants with
chair stand-based probable sarcopenia were generally
heavier and more obese. This indicates that the two pri-
mary tests for sarcopenia may include individuals with
contrasting features relative to non-sarcopenic individ-
uals, even when accounting for major influencing factors
such as age and sex. Compared to grip strength, chair
stand performance likely depends more on the partici-
pant having sufficient leg muscle strength to lift their
bodyweight [26], which may explain why the chair
stand-based probable sarcopenia group were heavier
compared the others. Adiposity may thus be a confound-
ing factor in chair stand performance not necessarily as-
sociated with the frail and thin phenotype that is more
common in participants with low grip strength. Longitu-
dinal studies are required to evaluate whether the differ-
ences in these phenotypes have an impact on health
outcomes. We also found that the EWGSOP2 cut-offs
for chair stands defined significantly more women than
men as sarcopenic, whereas for grip strength they did
not. Unlike the grip strength cut-offs, the EWGSOP2
chair stand cut-offs do not differ between men and
women [11]. Others have reported that women generally
perform poorer than men in the chair stand test, poten-
tially warranting sex-specific thresholds, although the
differences between men and women are less distinct
than for grip strength cut-off points [27].
Defining probable sarcopenia by either grip strength
or chair stands resulted in different associations to the
other sarcopenia parameters, where ALMheight
2 was
more strongly associated with grip strength-based prob-
able sarcopenia and TUG score was more strongly asso-
ciated with chair stand-based probable sarcopenia. The
relationship between chair stand and TUG performance
is plausible given the assessment procedure similarities.
The stronger association between grip strength and
ALMheight
2 compared to chair stands and ALMheight
2
was somewhat surprising, given the chair stand test’s
high correlation with leg muscle power, which in turn
correlates with leg muscle mass [28, 29]. Although, that
chair stand performance also relies on sensorimotor and
psychological capabilities rather than just muscle
strength may partly explain this finding [30]. The
discrepancy between upper- and lower body strength
measures, muscle mass and physical function could po-
tentially produce selection bias in the EWGSOP2 algo-
rithm steps when determining subsequent sarcopenia
confirmation and severity in individuals. This is partly
confirmed by the poor agreement and small overlap be-
tween grip strength and chair stand cut-offs, and that a
larger proportion of participants with grip strength-
based probable sarcopenia also had low ALMheight
2 and
met the criteria for confirmed sarcopenia, compared to
participants with chair stand-based probable sarcopenia.
The lack of agreement between the assessment methods
highlights the need to inform clinicians about the im-
portance of using both grip strength and chair stand
tests in sarcopenia screening, to properly identify all pa-
tients with probable sarcopenia according to the current
EWGSOP2 definition.
The EWGSOP2 definitions specify that muscle
strength can be determined by the grip strength test or
the five-repetition chair stand test, suggesting inter-
changeability of these measures [11]. However, previous
research have shown poor associations between upper-
and lower body strength [13, 14], and we report differ-
ences in anthropometric parameters and physical func-
tion when using either the grip strength- or chair stand
test to define probable sarcopenia. While usually pre-
ferred out of feasibility, studies show that grip strength
testing may be insufficient in detecting associations be-
tween muscle strength, hospitalization and mortality
[31]. Likewise, grip strength testing can be inadequate
when evaluating the efficacy of intervention programs,
while measures of leg strength are reportedly more sen-
sitive to change following exercise regimens [6, 32].
However, a recent meta-analysis reported 31% reduced
risk for all-cause mortality using grip strength compared
to 14% reduced risk when using knee extension strength,
adding further controversy as to whether upper-body or
lower-body strength is more important for health out-
comes [33].
The present study has some limitations that need ad-
dressing. Unfortunately, we did not have access to
harder sarcopenia endpoints such as fractures or mortal-
ity. It would have been valuable to investigate how the
differences between upper- and lower body strength
testing would influence such outcomes. We did not per-
form in-depth analyses of the confirmed or severe sarco-
penia stages due to relatively low numbers of
participants in these groups. It would have been of value
to explore whether probable sarcopenia classification
based on grip strength or chair stands also influenced
participant characteristics in later sarcopenia stages fur-
ther down the EWGSOP2 algorithm. However, the
EWGSOP2 state that probable sarcopenia often is
enough to initiate cause assessment and interventions in
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clinical practice [11]. Additionally, we could only include
3498 out of 8346 participants because they had complete
strength, physical function and body composition assess-
ments. Although, we post-hoc analyzed 7745 partici-
pants with only grip strength and chair stand tests
performed, and prevalence of probable sarcopenia,
smoking, CVD, as well as mean BMI were very similar
(see Additional file 2) to the current study results.
Conclusions
The present study showed that age-standardized preva-
lence of probable and confirmed sarcopenia was rela-
tively low (1.3–4.4%) in a population-based sample of
community-dwelling Norwegians aged 40–84 years. The
prevalence was more than twice as high across all ages
when using chair stands compared to grip strength as
the defining measure. Furthermore, the two strength
measures defined individuals with contradictory an-
thropometrics, body composition and physical function
to have probable sarcopenia. Researchers should further
explore the consequences of using different strength
measures in the EWGSOP2 algorithm, and evaluate
whether these can be used interchangeably to define
sarcopenia.
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